Home>>Signaling Pathways>> DNA Damage/DNA Repair>> CRISPR/Cas9>>NU7441 (KU-57788)

NU7441 (KU-57788) (Synonyms: KU 57788; NU-7441;KU57788;NU7441;NU 7441)

Catalog No.GC11251

NU7441 (KU-57788) (NU7441) is a highly potent and selective DNA-PK inhibitor with an IC50 of 14 nM. NU7441 (KU-57788) is an NHEJ pathway inhibitor. NU7441 (KU-57788) also inhibits PI3K and mTOR with IC50s of 5.0 and 1.7 μM, respectively.

Products are for research use only. Not for human use. We do not sell to patients.

NU7441 (KU-57788) Chemical Structure

Cas No.: 503468-95-9

Size Price Stock Qty
10mM (in 1mL DMSO)
$68.00
In stock
5mg
$35.00
In stock
25mg
$103.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

NU7441 is a selective inhibitor of DNA-dependent protein kinase (DNA-PK) with IC50 value of 13 nM [1].

NU7441 is an ATP-competitive inhibitor of DNA-PK and showed a Ki value of 0.65 nM. The inhibition of DNA-PK was selective. NU7441 showed no inhibition effect on the DNA-PK-related enzymes ATM and ATR at concentration of 100 μM. For mTOR and PI3K, NU7441 exerted inhibition activities with IC50 values of 1.7 and 5 μM, respectively, which were about 100-fold higher than the IC50 value of DNA-PK. In HeLa cells, treatment of NU7441 at concentration of 100 nM significantly enhanced the sensitivity of cells to etoposide and promoted cells to death. In mice bearing SW620 xenografts, coadministration of NU7441 and etoposide caused a tumor growth delay of 5.4 days which was twice longer than that caused by etoposide alone [1, 2].

References:
[1] Hardcastle I R, Cockcroft X, Curtin N J, et al. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. Journal of medicinal chemistry, 2005, 48(24): 7829-7846.
[2] Zhao Y, Thomas H D, Batey M A, et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer research, 2006, 66(10): 5354-5362.

Reviews

Review for NU7441 (KU-57788)

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for NU7441 (KU-57788)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.